Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.
anthracycline
chemotherapy
epithelioid haemangioendothelioma
interferon
paclitaxel
pazopanib
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
25
01
2021
received:
17
01
2021
accepted:
09
02
2021
pubmed:
14
3
2021
medline:
20
7
2021
entrez:
13
3
2021
Statut:
ppublish
Résumé
This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions. Twenty sarcoma reference centres contributed data. Patients with advanced EHE diagnosed from 2000 onwards and treated with systemic therapies, were selected. Local pathologic review and molecular confirmation were required. Radiological response was retrospectively assessed by local investigators according to RECIST. Progression free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method. Overall, 73 patients were included; 21 had more than one treatment. Thirty-three patients received anthracyclines regimens, achieving 1 (3%) partial response (PR), 25 (76%) stable disease (SD), 7 (21%) progressive disease (PD). The median (m-) PFS and m-OS were 5.5 and 14.3 months respectively. Eleven patients received paclitaxel, achieving 1 (9%) PR, 6 (55%) SD, 4 (36%) PD. The m-PFS and m-OS were 2.9 and 18.6 months, respectively. Twelve patients received pazopanib, achieving 3 (25%) SD, 9 (75%) PD. The m-PFS and m-OS were.2.9 and 8.5 months, respectively. Fifteen patients received INF-α 2b, achieving 1 (7%) PR, 11 (73%) SD, 3 (20%) PD. The m-PFS and m-OS were 8.9 months and 64.3, respectively. Among 27 patients treated with other regimens, 1 PR (ifosfamide) and 9 SD (5 gemcitabine +docetaxel, 2 oral cyclophosphamide, 2 others) were reported. Systemic therapies available for advanced sarcomas have limited activity in EHE. The identification of new active compounds, especially for rapidly progressive cases, is acutely needed.
Sections du résumé
BACKGROUND
This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions.
METHODS
Twenty sarcoma reference centres contributed data. Patients with advanced EHE diagnosed from 2000 onwards and treated with systemic therapies, were selected. Local pathologic review and molecular confirmation were required. Radiological response was retrospectively assessed by local investigators according to RECIST. Progression free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method.
RESULTS
Overall, 73 patients were included; 21 had more than one treatment. Thirty-three patients received anthracyclines regimens, achieving 1 (3%) partial response (PR), 25 (76%) stable disease (SD), 7 (21%) progressive disease (PD). The median (m-) PFS and m-OS were 5.5 and 14.3 months respectively. Eleven patients received paclitaxel, achieving 1 (9%) PR, 6 (55%) SD, 4 (36%) PD. The m-PFS and m-OS were 2.9 and 18.6 months, respectively. Twelve patients received pazopanib, achieving 3 (25%) SD, 9 (75%) PD. The m-PFS and m-OS were.2.9 and 8.5 months, respectively. Fifteen patients received INF-α 2b, achieving 1 (7%) PR, 11 (73%) SD, 3 (20%) PD. The m-PFS and m-OS were 8.9 months and 64.3, respectively. Among 27 patients treated with other regimens, 1 PR (ifosfamide) and 9 SD (5 gemcitabine +docetaxel, 2 oral cyclophosphamide, 2 others) were reported.
CONCLUSION
Systemic therapies available for advanced sarcomas have limited activity in EHE. The identification of new active compounds, especially for rapidly progressive cases, is acutely needed.
Identifiants
pubmed: 33713582
doi: 10.1002/cam4.3807
pmc: PMC8026938
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2645-2659Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Transplantation. 2002 Jul 15;74(1):128-30
pubmed: 12134111
Anticancer Res. 2015 Jan;35(1):473-80
pubmed: 25550590
Lancet Oncol. 2017 Aug;18(8):1089-1103
pubmed: 28651927
Acta Oncol. 2020 Aug;59(8):975-982
pubmed: 32476528
Acta Oncol. 2017 Jan;56(1):88-92
pubmed: 27838944
Clin Sarcoma Res. 2015 Apr 23;5:12
pubmed: 25969727
Genes Chromosomes Cancer. 2013 Aug;52(8):775-84
pubmed: 23737213
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28598585
Cancer. 2021 Feb 15;127(4):569-576
pubmed: 33107985
Genes Chromosomes Cancer. 2011 Aug;50(8):644-53
pubmed: 21584898
J Neurooncol. 2010 Apr;97(2):275-7
pubmed: 19898746
Oncology. 1997 Mar-Apr;54(2):171-5
pubmed: 9075791
J Clin Oncol. 2008 Nov 10;26(32):5269-74
pubmed: 18809609
Lancet Oncol. 2006 May;7(5):439-41
pubmed: 16648050
Nat Rev Urol. 2009 Apr;6(4):223-7
pubmed: 19352397
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
JAMA. 2020 Apr 7;323(13):1266-1276
pubmed: 32259228
Mod Pathol. 2020 Apr;33(4):591-602
pubmed: 31537895
Medicine (Baltimore). 2018 Oct;97(42):e12795
pubmed: 30334971
J Pediatr Hematol Oncol. 2020 Nov;42(8):e826-e829
pubmed: 31714437
Genes Chromosomes Cancer. 2020 Jul;59(7):389-395
pubmed: 32170768
Hepatobiliary Pancreat Dis Int. 2020 Feb;19(1):29-35
pubmed: 31822393
J Clin Oncol. 2011 Sep 1;29(25):e722-4
pubmed: 21788568
Cancers (Basel). 2018 Jul 10;10(7):
pubmed: 29996478
Pneumonol Alergol Pol. 2008;76(4):281-5
pubmed: 18785134
Cancer. 2013 Jul 15;119(14):2639-44
pubmed: 23589078
Medicine (Baltimore). 2017 Nov;96(45):e8507
pubmed: 29137048
Pediatr Blood Cancer. 2020 Feb;67(2):e28045
pubmed: 31724797
Lancet Oncol. 2005 Oct;6(10):813-5
pubmed: 16198988
J Clin Oncol. 2015 Sep 1;33(25):2797-802
pubmed: 26215950
Chest. 2011 Nov;140(5):1312-1318
pubmed: 21546438
Ann Oncol. 2013 Jan;24(1):257-63
pubmed: 22910841
Ann Surg. 2007 Dec;246(6):949-57; discussion 957
pubmed: 18043096
BMC Cancer. 2015 May 13;15:402
pubmed: 25967676
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336